Results 61 to 70 of about 87,055 (290)
AARS1 drives PI3K–AKT–mTOR‐dependent glycolysis in bladder cancer, promoting lactate accumulation, increased lactylation, H3K27la enrichment at the HK2 promoter, and HK2 transcription. HK2 reinforces glycolysis, sustaining a metabolic–epigenetic program associated with tumor progression, recurrence, and metastasis.
Qin Yuan +13 more
wiley +1 more source
Suhua Wang,1,2 Siyuan Han,1,2 Weiyan Cheng,1,2 Ruoyang Miao,1,2 Shasha Li,1,2 Xin Tian,1,2 Quancheng Kan1,2 1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People’s Republic of China; 2Henan Key ...
Wang S +6 more
doaj
Design and Synthesis of Hybrid Compounds as Epigenetic Modifiers
Epigenetic modifiers acting through polypharmacology mechanisms are promising compounds with which to treat several infectious diseases. Histone deacetylase (HDAC) enzymes, mainly class I, and extra-terminal bromodomains (BET) are involved in viral ...
Juliana Romano Lopes +4 more
doaj +1 more source
SOX2 upregulates KAT7 in glioma stem cells, where KAT7 deposits H3K14 acetylation at the RAC2 promoter to activate RAC2 transcription. RAC2‐GTP subsequently promotes PAK1/2/3 phosphorylation, increasing tricarboxylic acid cycle flux and mitochondrial respiration to support glioblastoma malignancy.
Jilong Liu +13 more
wiley +1 more source
Disabling COMPASS Promoter Licensing Shifts HDAC‐Inhibited Gastric Cancer Toward Sustained Transcriptional Suppression During Recovery [PDF]
Combined inhibition of the WDR5 WIN pocket and HDAC activity converts SAHA‐induced hyperacetylation into a promoter state with reduced WDR5–COMPASS association and H3K4me3. MYC/E2F‐linked nascent transcription and biosynthetic recovery are suppressed, while apoptosis and senescence‐like features increase, resulting in sustained growth inhibition in ...
Song J +8 more
europepmc +2 more sources
A low dose of dexmedetomidine, delivered by ROS‐responsive nanoparticles, preferentially accumulates in the ischemic intestine and restores gut vascular barrier integrity after ischemia/reperfusion injury. This nanoparticle‐based strategy prevents bacterial translocation and liver damage without cardiorespiratory side effects, working through HDAC ...
Hu‐Fei Zhang +10 more
wiley +1 more source
Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brain. [PDF]
Histone deacetylase (HDAC) inhibition has promise as a therapy for Alzheimer's disease (AD) and other neurodegenerative diseases. Currently, therapeutic HDAC inhibitors target many HDAC isoforms, a particularly detrimental approach when HDAC isoforms are
Kyle W Anderson +5 more
doaj +1 more source
Histone deacetylases (HDACs) have been associated with human malignant tumor development and progression, and HDAC inhibitors are currently being explored as anticancer agents in clinical trials. The present study aimed to evaluate the clinical significance of HDAC-1, HDAC-2, HDAC-4, and HDAC-6 proteins' expression in human malignant and benign thyroid
Giaginis, C. +5 more
openaire +3 more sources
Pathological tissue rigidity mechanoprimes microglia by enhancing actin cytoskeleton–nucleus coupling and chromatin opening at rigidity‐responsive cis‐regulatory elements (mechanoCREs). Subsequent NF‐κB/p65 signaling converges on this permissive regulatory state to amplify inflammatory gene expression and microglial activation.
Yu Xuan Meng +15 more
wiley +1 more source
Human gut bacteria as potent class I histone deacetylase inhibitors in vitro through production of butyric acid and valeric acid. [PDF]
Overexpression of histone deacetylase (HDAC) isoforms has been implicated in a variety of disease pathologies, from cancer and colitis to cardiovascular disease and neurodegeneration, thus HDAC inhibitors have a long history as therapeutic targets.
Samantha Yuille +4 more
doaj +1 more source

